Table 1.

Characteristics of Eligible Patients.

Characteristic		No. (%)
	A3973 (n=34)	ANBL0532 (n=27)	A3973 + ANBL0532 (n=61)	ANBL00B1 [not in A3973 or ANBL0532] (n=72)	ANBL14B8 Cohort (n=101)
Age at diagnosis, months (median, range)	40.49 (18.27, 189.08)	33.51 (18.04, 235.30)	37.55 (18.04, 235.30)	36.99 (18.14, 240.23)	36.86 (18.04, 240.23)
A3973 Enrollments	34 (100.00)	0 (0.00)	34 (55.74)	--	6 (5.94)
ANBL0532 Enrollments	0 (0.00)	27 (100.00)	27 (44.26)	--	23 (22.77)
Sex
• Female	18 (52.94)	17 (62.96)	35 (57.38)	36 (50.00)	53 (52.48)
• Male	16 (47.06)	10 (37.04)	26 (42.62)	36 (50.00)	48 (47.52)
Primary site
• Adrenal	6 (18.18)	6 (23.08)	12 (20.34)	13 (18.84)	18 (18.56)
• Abdominal, other	20 (60.61)	14 (53.85)	34 (57.63)	38 (55.07)	55 (56.70)
• Neck	--	--	--	3 (4.35)	3 (3.09)
• Thorax	4 (12.12)	3 (11.54)	7 (11.86)	6 (8.70)	8 (8.25)
• Other	3 (9.09)	3 (11.54)	6 (10.17)	9 (13.04)	13 (13.40)
• Unknown	1	1	2	3	4
Response after induction therapy
• Complete/Very Good Partial Response	20 (64.52)	19 (73.08)	39 (68.42)
• Partial Response	10 (32.26)	3 (11.54)	13 (22.81)
• No/Mixed Response	--	1 (3.85)	1 (1.75)
• Progressive Disease	1 (3.23)	3 (11.54)	4 (7.02)
• Not Evaluated or Missing	3	1	4
Immunotherapy on ANBL0032 or ANBL0931	3 (8.82)	20 (74.07)	23 (37.70)	16 (22.22)	34 (33.66)
Relapse	7 (20.59)	10 (37.04)	17 (27.87)	12 (16.67)	23 (22.77)
• Local	1 (2.94)	4 (14.81)	5 (8.20)	4 (5.56)	8 (7.92)
• Metastatic	5 (14.71)	4 (14.81)	9 (14.75)	7 (9.72)	12 (11.88)
• Local + Metastatic	1 (2.94)	2 (7.41)	3 (4.92)	1 (1.39)	3 (2.97)
5-year EFS ± standard error	73.0 ± 8.1	61.4 ± 10.2	68.0 ± 6.4	71.1 ± 6.2	67.9 ± 5.3
5-year OS ± standard error	87.9 ± 5.9	73.0 ± 9.2	81.6 ± 5.3	78.8 ± 5.5	77.7 ± 4.7